2.170USD-10.70%Mkt Cap: 40.08M USDP/E: —Last update: 2026-05-26
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company dev…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap40.08M USD
Enterprise Value39.57M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-26.98M USD
Revenue/Share—
Last Price2.170 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees6
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS4831192020
Valuation
P/E (Trailing)—
P/E (Forward)-0.39
PEG—
EV/EBITDA-1.19
EV/Revenue—
P/S—
P/B0.21
EPS (TTM)-102.01
EPS (Forward)-6.67
52W Range
2.1500% of range1030.00
52W High1030.00 USD
52W Low2.150 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-385.65%
ROA-284.30%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-31.99M USD
CapEx (TTM)15.00K USD
FCF Margin—
FCF Yield-48.58%
Net Debt-8.76M USD
Net Debt/EBITDA0.26
Balance Sheet
Debt/Equity0.00
Current Ratio7.91
Quick Ratio5.63
Book Value/Sh12.56 USD
Cash/Share0.4710 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateMay 11, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.18.59M
Float18.59M
Insiders1.30%
Institutions0.63%
Short Interest
Short Ratio0.3d
Short % Float0.11%
Short % Out.0.11%
Shares Short20.58K
Short (prev mo.)22.75K
Technical
SMA 507.917 (-72.6%)
SMA 200141.11 (-98.5%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)81.92K
Avg Vol (10d)93.40K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—